Senior/Executive Director, Alliance Management

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

The Senior/Executive Director of Alliance Management will play a critical role in fostering and managing strategic partnerships. This individual will be responsible for leading and overseeing the management of strategic partnerships, developing and executing alliance strategies, fostering collaboration between internal teams and external partners, and ensuring that partnerships delivery mutual value.

Essential Job Functions

• Develop and implement the overall alliance management strategy aligned with the organization's business objectives and goals.
• Facilitate and coordinate joint committees and working groups to promote collaboration among partners.
• Monitor and manage ongoing alliance performance, addressing any issues that arise to strengthen the partnership.
• Serve as the primary point of contact for partners, maintaining strong relationships and clear communication.
• Collaborate with internal teams, including research, development, and commercial operations, to support partnership initiatives.
• Analyze and report on alliance performance metrics, providing insights for continuous improvement.
• Establish communication and decision-making protocols among alliance teams and with the partner; ensures contractually required communication occurs in a timely manner.
• Accurately interpret contracts and manages contractual obligations; establish and monitor metrics and milestones; negotiate amendments to contracts; and manage conflict resolutions and escalation when necessary.
  
  

Job Requirements

• Advanced degree in life sciences, business administration, or a related field is preferred.
• Proven experience in alliance management or partnership development within the pharmaceutical biotechnology industry.
• Strong negotiation and communication skills, with the ability to manage complex relationships.
• Expertise in deal negotiation and post-deal management.
• Strategic thinking and problem-solving abilities, with a focus on achieving mutual goals.
• Expertise in working within matric teams, including cross-cultural teams and influencing without authority.
• Experience working with a broad range of functions including commercial, business development, R&D, finance and legal.
  
  

The base range for a Senior Director is $248,160 - $284,939 and Executive Director is $278,330 - $316,347 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura's Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves
  
  

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
  
  

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura's pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.